144 related articles for article (PubMed ID: 1329789)
1. Leigh encephalopathy: histologic and biochemical analyses of muscle biopsies.
Nagai T; Goto Y; Matsuoka T; Sakuta R; Naito E; Kuroda Y; Nonaka I
Pediatr Neurol; 1992; 8(5):328-32. PubMed ID: 1329789
[TBL] [Abstract][Full Text] [Related]
2. [Defects of pyruvate metabolism in cultured lymphoblastoid cells of 20 patients with Leigh syndrome].
Naito E; Ito M; Yokota I; Saijo T; Matsuda J; Osaka H; Kimura S; Kuroda Y
No To Hattatsu; 1996 Nov; 28(6):495-500. PubMed ID: 8940876
[TBL] [Abstract][Full Text] [Related]
3. The mitochondrial DNA G13513A MELAS mutation in the NADH dehydrogenase 5 gene is a frequent cause of Leigh-like syndrome with isolated complex I deficiency.
Chol M; Lebon S; Bénit P; Chretien D; de Lonlay P; Goldenberg A; Odent S; Hertz-Pannier L; Vincent-Delorme C; Cormier-Daire V; Rustin P; Rötig A; Munnich A
J Med Genet; 2003 Mar; 40(3):188-91. PubMed ID: 12624137
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome c oxidase activity is deficient in blood vessels of patients with myoclonus epilepsy with ragged-red fibers.
Hasegawa H; Matsuoka T; Goto Y; Nonaka I
Acta Neuropathol; 1993; 85(3):280-4. PubMed ID: 8384773
[TBL] [Abstract][Full Text] [Related]
5. G8363A mutation in the mitochondrial DNA transfer ribonucleic acidLys gene: another cause of Leigh syndrome.
Shtilbans A; Shanske S; Goodman S; Sue CM; Bruno C; Johnson TL; Lava NS; Waheed N; DiMauro S
J Child Neurol; 2000 Nov; 15(11):759-61. PubMed ID: 11108511
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome oxidase immunohistochemistry: clues for genetic mechanisms.
Rahman S; Lake BD; Taanman JW; Hanna MG; Cooper JM; Schapira AH; Leonard JV
Brain; 2000 Mar; 123 Pt 3():591-600. PubMed ID: 10686181
[TBL] [Abstract][Full Text] [Related]
7. The G13513A mutation in the ND5 gene of mitochondrial DNA as a common cause of MELAS or Leigh syndrome: evidence from 12 cases.
Shanske S; Coku J; Lu J; Ganesh J; Krishna S; Tanji K; Bonilla E; Naini AB; Hirano M; DiMauro S
Arch Neurol; 2008 Mar; 65(3):368-72. PubMed ID: 18332249
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of MELAS and mitochondrial DNA mutations.
Goto Y
Muscle Nerve Suppl; 1995; 3():S107-12. PubMed ID: 7603510
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome C oxidase-deficient mitochondria in mitochondrial myopathy.
Haginoya K; Miyabayashi S; Iinuma K; Okino E; Maesaka H; Tada K
Pediatr Neurol; 1992; 8(1):13-8. PubMed ID: 1313674
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome C oxidase deficiency in two siblings with Leigh encephalomyelopathy.
Miyabayashi S; Narisawa K; Iinuma K; Tada K; Sakai K; Kobayashi K; Kobayashi Y; Morinaga S
Brain Dev; 1984; 6(4):362-72. PubMed ID: 6093613
[TBL] [Abstract][Full Text] [Related]
11. Novel mitochondrial DNA ND5 mutation in a patient with clinical features of MELAS and MERRF.
Naini AB; Lu J; Kaufmann P; Bernstein RA; Mancuso M; Bonilla E; Hirano M; DiMauro S
Arch Neurol; 2005 Mar; 62(3):473-6. PubMed ID: 15767514
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic heterogeneity in families with the myoclonic epilepsy and ragged-red fiber disease point mutation in mitochondrial DNA.
Graf WD; Sumi SM; Copass MK; Ojemann LM; Longstreth WT; Shanske S; Lombes A; DiMauro S
Ann Neurol; 1993 Jun; 33(6):640-5. PubMed ID: 8388680
[TBL] [Abstract][Full Text] [Related]
13. Clinical and laboratory survey of 65 Chinese patients with Leigh syndrome.
Yang YL; Sun F; Zhang Y; Qian N; Yuan Y; Wang ZX; Qi Y; Xiao JX; Wang XY; Qi ZY; Zhang YH; Jiang YW; Bao XH; Qin J; Wu XR
Chin Med J (Engl); 2006 Mar; 119(5):373-7. PubMed ID: 16542579
[TBL] [Abstract][Full Text] [Related]
14. Increased mitochondrial DNA in blood vessels and ragged-red fibers in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS).
Tokunaga M; Mita S; Sakuta R; Nonaka I; Araki S
Ann Neurol; 1993 Mar; 33(3):275-80. PubMed ID: 7684581
[TBL] [Abstract][Full Text] [Related]
15. Atypical clinical presentations associated with the MELAS mutation at position 3243 of human mitochondrial DNA.
Moraes CT; Ciacci F; Silvestri G; Shanske S; Sciacco M; Hirano M; Schon EA; Bonilla E; DiMauro S
Neuromuscul Disord; 1993 Jan; 3(1):43-50. PubMed ID: 8392410
[TBL] [Abstract][Full Text] [Related]
16. Pyruvate therapy for Leigh syndrome due to cytochrome c oxidase deficiency.
Komaki H; Nishigaki Y; Fuku N; Hosoya H; Murayama K; Ohtake A; Goto Y; Wakamoto H; Koga Y; Tanaka M
Biochim Biophys Acta; 2010 Mar; 1800(3):313-5. PubMed ID: 19616603
[TBL] [Abstract][Full Text] [Related]
17. [Mitochondrial dysfunction and brain development disorders].
Goto Y
No To Shinkei; 2001 May; 53(5):421-6. PubMed ID: 11424352
[No Abstract] [Full Text] [Related]
18. Mitochondrial DNA mutations in Leigh syndrome and their phylogenetic implications.
Makino M; Horai S; Goto Y; Nonaka I
J Hum Genet; 2000; 45(2):69-75. PubMed ID: 10721666
[TBL] [Abstract][Full Text] [Related]
19. Comparative biochemical studies in fibroblasts from patients with different forms of Leigh syndrome.
Vazquez-Memije ME; Shanske S; Santorelli FM; Kranz-Eble P; Davidson E; DeVivo DC; DiMauro S
J Inherit Metab Dis; 1996; 19(1):43-50. PubMed ID: 8830176
[TBL] [Abstract][Full Text] [Related]
20. Revelation of a new mitochondrial DNA mutation (G12147A) in a MELAS/MERFF phenotype.
Melone MA; Tessa A; Petrini S; Lus G; Sampaolo S; di Fede G; Santorelli FM; Cotrufo R
Arch Neurol; 2004 Feb; 61(2):269-72. PubMed ID: 14967777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
